Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: A study of Malindi Town, Kenya

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Njomo, Doris W ^a   Mukoko, Dunstan A ^b   Nyamongo, Nipher K ^a   Karanja, Joan ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b MINISTRY OF HEALTH   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AWARENESS; COMMUNITY CARE; CONTROLLED STUDY; DISEASE ELIMINATION; FEMALE; HEALTH CARE DISTRIBUTION; HEALTH CARE MANAGEMENT; HOUSEHOLD; HUMAN; INFORMATION SEEKING; INTERVIEW; KENYA; LYMPHATIC FILARIASIS; MALE; MASS DRUG ADMINISTRATION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; QUASI EXPERIMENTAL STUDY; QUESTIONNAIRE; SOCIAL PARTICIPATION; SOCIAL STATUS; URBAN AREA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CITIES; ELEPHANTIASIS, FILARIAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMATION DISSEMINATION; KENYA; MALE; MEDICATION SYSTEMS; MIDDLE AGED; PUBLIC HEALTH PRACTICE; PUBLIC OPINION; YOUNG ADULT;

EID: 84898005048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083413     Document Type: Article

References (32)

1. World Health Organization (1995b) World Health Report, Geneva. pp118.
2. World Health Organization (2000c) Operational guidelines for rapid mapping of Bancroftian filariasis in Africa World Health Organization.
3. World Health Organization (2004) Lymphatic filariasis: progress of disability prevention activities. Wkly Epidemiol Rec 79: 417-24.
4. Bockarie M, Molyneux D (2009) The end of lymphatic filariasis? Tropical Diseases. British Medical Journal 338: b 1686.
5. Micheal E, Bundy DA, Grenfell BT (1996)Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112: 409-428. (Pubitemid 26126021)
6. Njenga SM, Wamae CN, Njomo DW, Mwandawiro CS, Molyneux DH (2008) Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on Wuchereriabancrofti infection and the sensitivity of immunochromatographic test in Malindi, Kenya. Trans R Soc Trop Med Hyg 102: 1017-1024.
7. Centres for Disease Control and Prevention (1993) Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 42: 1-38.
8. Moulia-Pelat JP, Glaziou P, Weil GJ, Nguyen LN, Gaxotte P, et al. (1995) Combination ivermectin plus diethylcarbamazine, a new effective tool for control of lymphatic filariasis. Trop Med Parasitol 46: 9-12
9. Ottesen EA, Ramachandran C (1995) Lymphatic filariasis infection and disease: Control Strategies. Parasitology Today 11: 129-131
10. Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS, et al. (1998) Efficacy of single dose combination of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 92: 94-97. (Pubitemid 28073744)
11. Ottesen EA (2000) The global programme to eliminate lymphatic filariasis. Trop Med Int Health 5:591-594.
12. Lammie P, Milner T, Houston R (2007) Unfulfilled potential, using diethylcarbamazine- fortified salt to eliminate lymphatic filariasis. Bull World Health Organ 85:545-9. (Pubitemid 47041633)
13. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD (2003) Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188: 1371-1381. (Pubitemid 37433710)
14. Plaisier AP, Subramanian S, Das PK, Souza W, Lapa T, et al. (1998) The LYMFASIM simulation program for modeling lymphatic filariasis and its control. Methods Inf Med 37:97-108. (Pubitemid 28154764)
15. Ichimori K, Ottesen EA (2011) Eliminating Lymphatic Filariasis. Bol Med Hosp Infant Mex 68 (2): 1-6.
16. World Health Organization (2008) Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration. Wkly Epidemiol Rec 83: 333-348.
17. Weerasooriya MV, Yahathugoda CT, Wickramasinghe D, Gunawardena KN,Dharmadasa RA, et al. (2007) Social mobilization, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka. Filaria J 6: 6-11.
18. Babu BV, Kar SK (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa India. Trop Med Int Health 9: 702-709. (Pubitemid 38833335)
19. World Health Organization (2004) Lymphatic Filariasis Elimination Programme. Training module for drug distributors in countries where lymphatic filariasis is not co-endemic with onchocerciasis.
20. Njomo DW, Amuyunzu-Nyamongo M, Mukoko DA, Magambo JK, Njenga SM. (2012) Socio-economic factors associated with Compliance with Mass Drug Administration for Lymphatic Filariasis Elimination in Kenya: Descriptive study results. Ann Trop Med Public Health 5: 103-10.
21. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Ngure PK, Njenga SM (2012) Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. South Afr J Epidemiol Infect 2: 66-70.
22. Kenya Population and housing census highlights (2009) Kenya National Bureau of Statistics. pp. 1-8.
23. Carter A (2010) Factors that contribute to the low uptake of skilled care during delivery in Malindi, Kenya. SIT Study Abroad.
24. Khan ME, Anker M, Patel BC, Barge S, Sadhwani H, et al. (1991) The use of focus groups in social and behavioral research: some methodological issues. World HealthStatistics Quarterly 44: 145-149.
25. Nandha B, Sadanandane C, Jambulingam P, Das PK (2007) Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, South India: 5 years of experience. Filaria Journal 6: 7 doi:10.1186/1475-2883-6-7.
26. Aswathy S, Beteena K, Leelamoni K (2009) Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala. Annals ofTropical Medicine & Parasitology Vol. 103, 7: 617-624.
27. Yirga D, Deribe K, Woldemicheal K, Wendafrash M, Kassahun W (2010) Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia. Parasites and Vectors 3:3-48
28. Njomo DW, Amuyunzu-Nyamongo M, Mukoko DA, Magambo JK, Njenga SM (2012) Social Mobilization and Compliance with Mass Treatment for Lymphatic Filariasis Elimination in Kenya. Afr J Health Sci 20: 42-49.
29. Amarillo ML, Belizario VY Jr, Sadiang-abay JT, Sison SA, Dayag AM (2008) Factors associated with acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites and Vectors 1: 1-14.
30. Kyelem D, Biswass G, Bockarie MJ, Bradley MH, El-Setouhy M, et al. (2008). Determinants of Success in National Programs to Eliminate Lymphatic Filariasis: A Perspective Identifying Essential Elements and Research Needs. Amer Journal Trop MedHyg 79(4): 480-484.
31. Muralidhar MK, Veena GK, Sujatha K, Darshan BB, Varun NA (2013) Coverage and compliance of mass drug administration programme against filariasis in Bijapur District, Karnataka. J Pub Health Med Res 1(1):1-4.
32. Ranganath TS, Reddy NR (2012) Elimination of Lymphatic Filariasis, Mass Drug Administration in Endemic Areas of (Bidar District) Karnataka. Indian J Community Med 37: 219-22.